Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses | Zendy

Simbarashe Zvada | Zendy; Paolo Denti | Zendy; P. R. Donald | Zendy; H. Simon Schaaf | Zendy; Stephanie Thee | Zendy; James A. Seddon | Zendy; H. I. Seifart | Zendy; Philip Smith | Zendy; Helen McIlleron | Zendy; Ulrika S. H. Simonsson | Zendy

Open Access

Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses

Author(s) -

Simbarashe Zvada,

Paolo Denti,

P. R. Donald,

H. Simon Schaaf,

Stephanie Thee,

James A. Seddon,

H. I. Seifart,

Philip Smith,

Helen McIlleron,

Ulrika S. H. Simonsson

Publication year - 2014

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkt524

Subject(s) - pyrazinamide , rifampicin , isoniazid , medicine , pharmacokinetics , population , dosing , pharmacology , bioavailability , tuberculosis , volume of distribution , environmental health , pathology

To describe the population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children and evaluate the adequacy of steady-state exposures.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research